Teva CEO Offers Small Insights Into Big Priorities As Run Up to Dec. 11
This article was originally published in The Pink Sheet Daily
Teva CEO Jeremy Levin provided additional glimpses of the company’s new strategy on a Q3 earnings call in advance of an investor meeting on Dec. 11, where he and Teva management will reveal their full agenda. Levin again put the emphasis on “focus” and “discipline” over “pure growth,” confirmed the company’s ‘confidence in the MS drug laquinimod, and highlighted several senior management appointments that reflect Teva’s new priorities.
You may also be interested in...
In a flurry of recent activity with Korean pharmas, Handok confirms it is in acquisition talks with Teva, and Ildong inks licensing deal with TG Therapeutics.
Predictions of heightened M&A activity among smaller South Korean generic drug firms gained firmer ground this week after an offhand comment by a government official pointed to interest by Teva in a mid-tier firm.
FDA approved Aubagio for patients with relapsing forms of multiple sclerosis on Sept. 12. Sponsor Genzyme, owned by Sanofi, announced an annual price of $45,000 for the drug, below the only other oral therapy for MS, Novartis’ Gilenya.